Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Tachyon Ventures is a venture capital firm based in Los Angeles, founded in 2017. The firm focuses on early-stage companies in the fields of medicine, biotech, and bioengineering. Tachyon Ventures aims to provide smart capital to entrepreneurs who are advancing scientific research and technology. The organization collaborates with a network of scientists from leading research institutions, enhancing the support for their portfolio companies and ensuring a strong foundation for innovation.
Currently, Tachyon Ventures manages a portfolio of 13 companies, emphasizing investments in transformative technologies. The firm has established a reputation for backing scientific teams with protected intellectual property, which is crucial for maintaining competitive advantages in the biotech sector. Their investment strategy is characterized by a concentrated, conviction-led model, allowing them to focus on a select number of promising startups.
Notable milestones include their investment in Mammoth Biosciences, a company co-founded by Nobel laureate Jennifer Doudna, which has achieved unicorn status. Tachyon Ventures continues to expand its influence in the biotech space, leveraging its connections and expertise to support the growth of its portfolio companies.
Tachyon Ventures specializes in early-stage investments across several sectors, including biotech, healthcare, and regenerative medicine. Their investment stages range from pre-seed to Series A, allowing them to engage with startups at various points in their development. The firm emphasizes scientific risk-arbitrage in its investment thesis, which enables them to identify and support transformative technologies early in their lifecycle.
Investment criteria include a strong focus on companies with protected intellectual property, as well as teams recognized for their world-class research capabilities. Tachyon Ventures seeks to partner with scientist-founder teams who have foundational IP developed through collaboration with their scientific co-founders. This approach aligns with their venture-creation model, which may involve additional support through associated labs like Tachyon Valley Biolabs.
Geographically, Tachyon Ventures primarily invests in the United States, concentrating on companies that are innovating within the life sciences sector. Their portfolio reflects a commitment to advancing scientific research and technology, particularly in areas such as immunotherapy, gene therapy, and organ engineering.
Tachyon Ventures has built a diverse portfolio of 13 companies, each contributing to advancements in biotech and healthcare. Notable companies include:
This portfolio showcases Tachyon Ventures' commitment to supporting innovative solutions in healthcare and drug development, with a strong emphasis on scientific research and technology.
Cristina Escoda - Managing Partner. Cristina has extensive experience in venture capital and has been instrumental in guiding Tachyon Ventures' investment strategy. She has a strong background in biotech and healthcare investments.
Ernest Turro - Chief Scientific Partner. Ernest brings a wealth of scientific expertise to the firm, having worked with leading research institutions. His role involves evaluating the scientific merit of potential investments.
Josep Turro - Investment Committee Member. Josep has a background in finance and venture capital, contributing to the decision-making process for investments.
Neil Deramchi - Associate. Neil supports the investment team in sourcing and evaluating potential deals, with a focus on early-stage biotech companies.
Submit your pitch through their website's contact form for consideration.
In recent months, Tachyon Ventures has made significant investments in several biotech companies, including Mammoth Biosciences, Enclear Therapies, and DTx Pharma. These investments highlight the firm's commitment to supporting transformative life sciences ventures.
On April 15, 2026, Tachyon Ventures announced a new investment in Scipher Medicine, a company focused on precision immunology. This investment aligns with their strategy of backing companies that demonstrate strong scientific foundations and innovative solutions in healthcare.
Additionally, Tachyon Ventures has been actively expanding its portfolio, showcasing its dedication to identifying and supporting early-stage companies that are advancing scientific research and technology.
What investment criteria does Tachyon Ventures prioritize?
Tachyon Ventures focuses on early-stage companies in biotech and healthcare, emphasizing protected intellectual property and strong scientific teams. They look for startups that demonstrate promising scientific innovations and have foundational IP developed through collaboration with scientists.
How can founders pitch to Tachyon Ventures?
Founders can reach out through the firm's website. A well-prepared pitch deck should include details about the technology, market potential, and the founding team's background. Warm introductions are preferred, but not mandatory.
What makes Tachyon Ventures different from other investors?
Tachyon Ventures distinguishes itself by its focus on scientific risk-arbitrage and its collaboration with a network of scientists from leading research institutions. This approach provides portfolio companies with access to expertise and resources that can accelerate their development.
What is the geographic scope of Tachyon Ventures' investments?
The firm primarily invests in companies based in the United States, concentrating on those innovating within the life sciences sector.
What is the typical check size for investments?
While specific check sizes are not disclosed, it is estimated that Tachyon Ventures writes checks ranging from $500K to $3M for seed-stage investments and participates in larger rounds as needed.
What kind of post-investment involvement does Tachyon Ventures have?
Tachyon Ventures actively supports its portfolio companies by leveraging its network of scientists and providing strategic insights. They may also engage in board involvement and follow-on investments as companies progress.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.